Northern Trust
MBRX icon

Northern Trust’s Moleculin Biotech MBRX Stock Holding History

Northern Trust’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-143
Closed -$46K – 4455
2023
Q4 		$46K Hold
143
– – ﹤0.01% 4248
2023
Q3 		$22.9K Hold
143
– – ﹤0.01% 4309
2023
Q2 		$31K Hold
143
– – ﹤0.01% 4323
2023
Q1 		$51.5K Buy
143
+19
+15% +$8.32K ﹤0.01% 4263
2022
Q4 		$49.1K Hold
124
– – ﹤0.01% 4290
2022
Q3 		$49K Hold
124
– – ﹤0.01% 4327
2022
Q2 		$67K Sell
124
-11
-8% -$6.4K ﹤0.01% 4319
2022
Q1 		$90K Hold
135
– – ﹤0.01% 4382
2021
Q4 		$94K Hold
135
– – ﹤0.01% 4440
2021
Q3 		$152K Hold
135
– – ﹤0.01% 4273
2021
Q2 		$186K Hold
135
– – ﹤0.01% 4183
2021
Q1 		$207K Buy
135
+95
+238% +$174K ﹤0.01% 4108
2020
Q4 		$71K Hold
40
– – ﹤0.01% 4182
2020
Q3 		$72K Buy
40
+2
+5% +$4.25K ﹤0.01% 4038
2020
Q2 		$82K Buy
38
+9
+31% +$21.3K ﹤0.01% 3962
2020
Q1 		$40K Hold
29
– – ﹤0.01% 3987
2019
Q4 		$61K Hold
29
– – ﹤0.01% 4022
2019
Q3 		$74K Buy
29
+8
+38% +$20.7K ﹤0.01% 3986
2019
Q2 		$60K Hold
21
– – ﹤0.01% 4054
2019
Q1 		$39K Hold
21
– – ﹤0.01% 4063
2018
Q4 		$50K Buy
21
+11
+110% +$31.6K ﹤0.01% 4051
2018
Q3 		$37K Hold
10
– – ﹤0.01% 4166
2018
Q2 		$41K Buy
10
+4
+67% +$16.4K ﹤0.01% 4143
2018
Q1 		$24K Hold
6
– – ﹤0.01% 4153
2017
Q4 		$25K Buy
6
+1
+20% +$4.33K ﹤0.01% 4137
2017
Q3 		$27K Hold
5
– – ﹤0.01% 4127
2017
Q2 		$21K Hold
5
– – ﹤0.01% 4178
2017
Q1 		$13K Buy
+5
New +$17.5K ﹤0.01% 4184

Other funds holding MBRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AWM
Atticus Wealth Management Palm Beach Gardens, Florida $420M AUM 23.31% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FIM
FWL Investment Management Dallas, Texas $456M AUM 60.63% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return

Northern Trust's MBRX Position: Q1 2024 in Review

Northern Trust sold out of Moleculin Biotech (MBRX) in Q1 2024, closing a stake of 143 shares — an estimated $46K sold.

Northern Trust first reported a position in MBRX in Q1 2017 and held it in 28 quarters. The position peaked at $207K in Q1 2021. 15 funds tracked by Wall St. Rank hold MBRX as of Q1 2024.

  • Northern Trust reported no remaining Moleculin Biotech position as of Q1 2024 after selling out during the quarter.
  • Northern Trust sold 143 Moleculin Biotech shares in Q1 2024, an estimated $46K.
  • Northern Trust first reported a position in Moleculin Biotech in Q1 2017 and held it in 28 quarters.
  • Northern Trust's Moleculin Biotech position peaked at $207K in Q1 2021.
  • 15 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2024.

Based on Northern Trust's 13F filing for Q1 2024, filed 14 May 2024.